Physicians treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma

Current Medical Research and Opinion

Volumn 26, Issue 4, 2010, Pages 957-963

  Hahn, Steven R ^a,b   Kotak, Sameer ^c   Tan, Jason ^d   Kim, Elizabeth ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Medintel On Call   (United States)

^c PFIZER INC   (United States)

^d HEALTHCORE INC   (United States)

Author keywords

Bimatoprost; Glaucoma; Latanoprost; Persistence; Prostaglandin analog; Travoprost

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MONOTHERAPY; PATIENT COMPLIANCE; RETREATMENT; TREATMENT PLANNING;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; CONTINUITY OF PATIENT CARE; GLAUCOMA; HUMANS; MEDICATION ADHERENCE; PHYSICIAN'S PRACTICE PATTERNS; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 77949530597     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003659012     Document Type: Article

References (26)

1. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-209
2. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880-2883
3. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology 2005;112:953-961
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-713
5. Stewart WC, Chorak RP, Hunt HH, et al. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993;116:176-181
6. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005;140:598-606
7. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137(1 Suppl):S3-12
8. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacother-apy in the management of glaucoma. Eur J Ophthalmol 2003;13 (Suppl 4):S44-52
9. Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005;16:114-121
10. Schwartz GF. Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma. Am J Ophthalmol 2004;137(1 Suppl):S1-2
11. Parrish RK, Palmberg P, Sheu WP, et al. A comparison of latanoprost, bima-toprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703
12. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53(Suppl 1):S93-105
13. Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging 1997;11:352-360
14. Rait JL. Systemic effects of topical ophthalmic beta-adrenoceptor antagonists. Aust N Z J Ophthalmol 1999;27:57-64
15. Lumigan [package insert]. Irvine, CA: Allergan, Inc., 2006
16. Travatan [package insert]. Fort Worth, TX: Alcon Laboratories, Inc., 2004
17. Travatan Z [package insert]. Fort Worth, TX: Alcon Laboratories, Inc., 2006
18. Xalatan [package insert]. New York, NY: Pfizer Inc., 2003
19. Zimmerman TJ, Hahn SR, Gelb L, et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009;25:145-152
20. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 2007;48:5052-5057
21. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology 2008; 115:1320-1327
22. Gelb L, Friedman DS, Quigley HA, et al. Physician beliefs and behaviors related to glaucoma treatment adherence: the Glaucoma Adherence and Persistency Study. J Glaucoma 2008;17:690-698
23. Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology 2007; 114:1599-1606
24. Schwartz GF, Tan J, Kotak S. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs. J Ocul Pharmacol Ther 2009;25:555-561
25. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular pros-taglandin therapy: a population-based, retrospective study. Clin Ther 2003; 25:1172-1185
26. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141 (1 Suppl):S28-33